HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib
Y. Wang(Tongji University), Fred R. Hirsch(Tisch Hospital), Caicun Zhou(Tongji University), G. Gao(Tongji University), Robert C. Doebele(Aurora University), Christopher J. Rivard(University of Colorado Denver), Paul A. Bunn(University of Colorado Denver), Seung Hee Yang(Friedrich-Alexander-Universität Erlangen-Nürnberg), D. Ross Camidge(University of Colorado Denver), Jun Zhang(OSF HealthCare), Tao Jiang(Tongji University), Hui Yu(University of Colorado Anschutz Medical Campus), Huiping Ji(Tongji University), Megan M. Tu(University of Colorado Cancer Center), Zhen Qin(Chinese Academy of Sciences), Tony L. Ng(University of Colorado Anschutz Medical Campus), Jinghui Jiang(Jiangsu Hengrui Medicine (China)), Qiang Wang(Jiangsu Hengrui Medicine (China)), Shengxiang Ren(Tongji University)
Cited by 217
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2017|2.4k
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
|Journal of Clinical Oncology|2004|2.4k